NCT01257607 is a Phase 2 clinical trial of MIM-D3 Ophthalmic Solution in Dry Eye, sponsored by Mimetogen Pharmaceuticals USA, Inc..

Who is sponsoring NCT01257607?

NCT01257607 is sponsored by Mimetogen Pharmaceuticals USA, Inc..

What drugs are being tested in NCT01257607?

Interventions in NCT01257607: MIM-D3 Ophthalmic Solution, Placebo Ophthalmic Solution.

Is NCT01257607 still recruiting?

NCT01257607 is currently completed. Last updated 15 August 2019.

Last reviewed 2019-08-15 · How we verify

NCT01257607

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 and 5% MIM-D3 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model

Completed Phase 2 Last updated 15 August 2019

What this trial tests

Phase 2 trial testing MIM-D3 Ophthalmic Solution in Dry Eye in 150 participants. Completed in 1 May 2011.

Timeline

1 November 2010

Primary endpoint
1 May 2011

1 May 2011

Quick facts

Lead sponsor	Mimetogen Pharmaceuticals USA, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	150
Start date	1 November 2010
Primary completion	1 May 2011
Estimated completion	1 May 2011
Sites	1 location across United States

Drugs / interventions tested

MIM-D3 Ophthalmic Solution — full drug profile →
Placebo Ophthalmic Solution — full drug profile →

Conditions studied

Dry Eye — all drugs for Dry Eye →

Sponsor

Mimetogen Pharmaceuticals USA, Inc. — full company profile →

Who can join

18 and older, any sex, with Dry Eye. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Corneal staining
Time frame: 28 days
Ocular surface damage

Sponsor's own description

The objective of this study is to compare the safety and efficacy of 1% MIM-D3 and 5% MIM-D3 to placebo for the treatment of the signs and symptoms of dry eye.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement.
Chang EE, Goldberg JL. · · 2012 · cited 254× · PMID 22349567 · DOI 10.1016/j.ophtha.2011.11.003
Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye.
Meerovitch K, Torkildsen G, Lonsdale J, Goldfarb H, et al · · 2013 · cited 45× · PMID 23836957 · DOI 10.2147/opth.s44688

Verify or expand the search:

Other recruiting trials for Dry Eye

Currently open trials in the same condition.

NCT07366944 — PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes · NA · recruiting
NCT07329712 — Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy · recruiting
NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
NCT07298811 — Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment · Phase 1, PHASE2 · recruiting
NCT07135193 — Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Ath · NA · active not recruiting

Other Mimetogen Pharmaceuticals USA, Inc. trials

Trials by the same sponsor.

NCT05848128 — Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye · Phase 3 · completed
NCT03925727 — Tavilermide Ophthalmic Solution for the Treatment of Dry Eye · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01257607 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mimetogen Pharmaceuticals USA, Inc.
Last refreshed: 15 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01257607.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing